Segall Bryant & Hamill LLC bought a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,968 shares of the company's stock, valued at approximately $921,000.
Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after buying an additional 273 shares during the period. Innealta Capital LLC bought a new stake in Amphastar Pharmaceuticals in the second quarter worth about $55,000. Blue Trust Inc. boosted its position in shares of Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock valued at $70,000 after buying an additional 309 shares during the period. Asset Management One Co. Ltd. bought a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock worth $85,000 after buying an additional 301 shares during the period. Institutional investors own 65.09% of the company's stock.
Wall Street Analysts Forecast Growth
AMPH has been the subject of a number of recent analyst reports. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a report on Friday. They set an "equal weight" rating and a $55.00 price objective for the company. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler reduced their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $60.33.
Read Our Latest Report on AMPH
Amphastar Pharmaceuticals Stock Up 2.0 %
Shares of AMPH stock traded up $0.91 on Friday, hitting $45.46. The stock had a trading volume of 410,772 shares, compared to its average volume of 414,981. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The business has a 50 day moving average price of $48.26 and a 200 day moving average price of $44.45. The company has a market cap of $2.19 billion, a PE ratio of 15.15, a P/E/G ratio of 0.89 and a beta of 0.82.
Insider Activity at Amphastar Pharmaceuticals
In other news, CFO William J. Peters sold 7,426 shares of the company's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the transaction, the chief financial officer now directly owns 94,103 shares of the company's stock, valued at approximately $4,898,061.15. This represents a 7.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Rong Zhou sold 4,000 shares of the firm's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now directly owns 118,388 shares of the company's stock, valued at $5,724,059.80. The trade was a 3.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,533 shares of company stock valued at $1,571,652 over the last ninety days. 27.10% of the stock is owned by company insiders.
About Amphastar Pharmaceuticals
(
Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
See Also
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
